Keywords
Epstein-Barr virus - human immunodeficiency virus - immunocompromised - intracranial
- leiomyoma - mesenchymal - primary
Introduction
Leiomyomas are benign tumours of mesenchymal origin (ideally non-metastasising) predominantly
seen in the genitourinary system. However, metastasis to distant organs like spinal
cord, breast, pleura, brain, rib and vertebrae, appendix, parametrium, heart, vessels,
bone, muscle, soft tissue, lymph node, and retroperitoneum have been reported.[[1]] Our search of literature revealed around 30 reported cases of primary intracranial
leiomyoma. In this article, we describe a case of primary intracranial leiomyoma in
an immunocompromised adult with a brief review of available literature.
Case History
A 46-year old male presented with the chief complaint of giddiness for an hour associated
with an episode of aphasia following which he had difficulty in speaking. He complained
of intermittent headaches for the past 6 years. The headache began as shooting type,
then progressed to dull type, localised to left temporal region. There were no exaggerating
or relieving factors, no history of trauma, no bowel and bladder disturbances.
He was a known case of HIV and Hepatitis B virus infection on antiretroviral therapy.
On Examination, the patient was afebrile with normal vital signs. Examination of the
central nervous system was unremarkable.
Investigations revealed that the patient had mild leukopenia 3.9 × 106 cells/μL, ESR-47 mm/hr, He was seropositive for both HIV and Hepatitis B surface
antigen (HBsAg).
Contrast enhanced Computed Tomography (CT) scan of the head was performed which showed
a well-defined heterogeneously hyper dense lesion [[Figure 1]] in the left middle cranial fossa measuring 4.1 × 3.5 × 3.2 cm with enhancement
post contrast [[Figure 2]], [[Figure 3]], [[Figure 4]]. Oedema noted in the left temporal and parietal lobe causing a midline shift of
5 mm to the contralateral side -suggestive of a left middle cranial fossa meningioma.
Figure 1: Axial non contrast CT of the brain showing a hyperdense lesion in the left temporal
region with perifocal edema
Figure 2: Axial post contrast CT brain showing enhancing lesion in the left temporal fossa
with perifocal edema
Figure 3: Sagittal reformat of post contrast CT brain showing the same lesion
Figure 4: Coronal reformat of post contrast CT brain showing the dural based location of the
lesion
Under general anaesthesia, left frontotemporal craniotomy with excision of the tumour
was done. The tumour was extra axial in location with clear demarcation with the adjacent
structures.
Histopathology revealed spindle cell neoplasm composed of cells arranged in broad
interlacing fascicles. Cells showed elongated, slender nuclei and indistinct cytoplasmic
border. Hyalinised stroma with 2-3 mitotic figures/hpf [[Figure 5]] and [[Figure 6]]. On immunohistochemistery, the tumour cells were positive for smooth muscle actin
(SMA), Vimentin and Desmin and negative for epithelial membrane antigen (EMA). This
confirmed the diagnosis of leiomyoma.
Figure 5: Microscopic images showing spindle cells arranged in broad interlacing fascicles
with elongated, slender nuclei
Figure 6: Microscopic images showing spindle cells arranged in broad interlacing fascicles
with elongated, slender nuclei
Discussion
Leiomyoma is a type of smooth muscle tumour considered to be a benign entity although
may occasionally metastasise resulting in lesions in distal sites like the brain.
Intracranial leiomyomas are rare, with the primary variety being even rarer. The first
report of primary intracranial leiomyoma was done by kroe et al. in 1968. They suggested that the origin of the tumour to be the vascular smooth
muscle [[2]] of the brain. Several cases were reported after kroe et al. - Most of which were in immunocompromised patients. There is a significant rise
in these immunosuppression related smooth muscle tumours in the recent decade due
to the advances in antiretroviral therapy and increase in number of organ transplants
and associated immunosuppressive therapies. These smooth muscle tumours may be either
benign -leiomyomas or malignant - leiomyosarcoma.
Our search of literature revealed about 30 cases [[3]],[[4]] of primary intracranial leiomyoma [[Table 1]] and [[Table 2]] reported, of which only 2 cases have been reported from India. The peak age of
incidence was between 25-50 years with the youngest and oldest patients of age 4 and
68 years respectively. There was a slight female preponderance with 17 of the 30 cases
being females.
Table 1
Review of literature
Year Author
|
Locaion of the lesion
|
Immune status
|
Gender
|
Age
|
HIV
|
EBV
|
SIZE in cm
|
Follow up and Recurrence
|
Others
|
1968 Kroe et al.
|
Sellar
|
NA
|
F
|
68
|
NA
|
NA
|
2.5-3.0
|
9 m, NR
|
-
|
1978 Thierauf & Weiland
|
Suprasellar
|
NA
|
F
|
4
|
NA
|
NA
|
4.0-5.0
|
NA
|
-
|
1992 Kazumoto and Matzumoto
|
R Temporal
|
NA
|
F
|
38
|
NA
|
NA
|
3.5
|
NA
|
-
|
1996 Lin et al./Lai PH
|
LTemporal
|
NA
|
F
|
20
|
NA
|
NA
|
3 × 2 × 1 cm
|
24 m, NR
|
Calcifications
|
1997 Wang et al.
|
R Temporal
|
NA
|
M
|
12
|
NA
|
NA
|
NA
|
56 m, NR
|
-
|
1998 Kleinscmidt et al.
|
Intra and supra sellar
|
NA
|
F
|
56
|
NA
|
|
3.2
|
6 m, Residual tumour
|
-
|
|
RCavernous sinus
|
Immunocompromised
|
F
|
34
|
|
(+)
|
1.2
|
4.5 m, Increase in size
|
-
|
1999 Kim et al.
|
R Temporoparietal
|
NA
|
F
|
40
|
NA
|
NA
|
4 × 4.5 × 7
|
NA
|
Calcifications
|
1999 Karpinski et al.
|
L Sphenoid ridge
|
Immunocompromised
|
M
|
26
|
(+)
|
(+)
|
3
|
NA
|
Synchronous intradura extramedullary at C2-3 level
|
1999 Bargiela et al.
|
L Occipital lobe
|
Immunocompromised
|
F
|
32
|
(+)
|
NA
|
5
|
Patient died due to other complication of HIV
|
Central necrosis
|
2000 Citow and Kranzler
|
R Clivus, Upper lobe of right lung
|
Immunocompromised
|
F
|
31
|
(+)
|
(-)
|
3
|
NA
|
Low MIB, denovo at both sites
|
2004 Kumar et al.
|
R Basal ganglia
|
Immunocompromised
|
M
|
10
|
(+)
|
(+)
|
4
|
6 m, NR
|
-
|
2006 Ali et al.
|
R Frontal floor
|
NA
|
F
|
29
|
NA
|
(-)
|
1.2
|
NA
|
-
|
2009 Zevgaridis
|
L Temporal pole
|
Immunocompromised
|
F
|
45
|
NA
|
(+)
|
4×4
|
7 yr, NR
Patient died due to unrelaed causes
Transplant
|
Table 2
Review of literature, continued
Year Author
|
Locaion of the lesion
|
Immune status
|
Gender
|
Age
|
HIV
|
EBV
|
SIZE in cm
|
Follow up and Recurrence
|
Others
|
2009
|
L Middle fossa
|
Immunocompetent
|
M
|
45
|
(-)
|
NA
|
1.5 × 2 cm
|
14 m, NR
|
Calcifications
|
Hua et al.
|
R Middle fossa
|
Immunocompetent
|
M
|
35
|
(-)
|
NA
|
2 × 3
|
18 m, NR
|
-
|
2010 Dorwal P
|
L Infratemporal fossa
|
Immunocompetent
|
M
|
17
|
(-)
|
(-)
|
5.4 × 5 × 6 cm
|
-
|
Calcifications Bone erosion
|
2011 Ibebuike
|
R Frontal lobe
|
Immunocompromised
|
M
|
37
|
(+)
|
(+)
|
4.8 × 4.6 × 5.2 cm
|
20 wks, NR
|
Invasion of SSS
|
2013 Linden E Fornoff
|
L Middle fossa
|
Immunocompetent
|
M
|
20
|
(-)
|
(-)
|
6 × 8 cm
|
Multifocal recurrence after 9 years, repeat surgery done, 135 mnths from first surgery
-NR
|
Bone invasion
|
2013 Andrew Ko
|
R Sellar
|
Immunocompetent
|
F
|
24
|
NA
|
NA
|
0.7 × 1 × 1.7
|
NA
|
|
2013 Andrew Ko
|
Sellar
|
Immunocompetent
|
M
|
50
|
NA
|
NA
|
3 × 2.5 × 2.5
|
NA
|
complex cyst
|
2013
|
Lohan et al.
|
L Sylvian fissure
|
Immunocompromised
|
F
|
55
|
NA
|
(+)
|
NA
|
NA
|
Transplant
|
2014 Issarachaikul
|
NA
|
Immunocompromised
|
F
|
34
|
(+)
|
(+)
|
NA
|
NA
|
-
|
|
NA
|
Immunocompromised
|
M
|
39
|
(+)
|
(+)
|
NA
|
NA
|
-
|
|
NA
|
Immunocompromised
|
F
|
32
|
(+)
|
(+)
|
NA
|
NA
|
-
|
|
NA
|
Immunocompromised
|
F
|
29
|
(+)
|
(+)
|
NA
|
NA
|
-
|
2016 Garces
|
L Lateral ventricle
|
Immunocompetent
|
M
|
30
|
(-)
|
(-)
|
1 × 1.2 × 1.9
|
2.5 yr-NR
|
-
|
2017 Upasana
|
L Frontal
|
Immunocompromised
|
M
|
43
|
(-)
|
(-)
|
2.73 × 1.20 cm
|
10 m, NR
|
Renal Transplant
|
2017 Raheja
|
L Cavernous sinus
|
Immunocompromised
|
F
|
65
|
(-)
|
(+)
|
0.6 × 0.8 × 1.2 cm
|
3 mnths, Stable
|
ALL with allogenic peripheral blood stem cell transplantation
|
2018 Current case
|
L Temporal
|
Immunocompromised
|
M
|
46
|
(+)
|
NA
|
4 × 3.5 × 3.2 cm
|
-
|
-
|
Site: The commonest reported site of occurrence was the middle cranial fossa/temporal
lobe followed by the sellar/parasellar/cavernous region. Other reported sites include
basal ganglia, frontal region and intraventricular in the lateral ventricle.
Size: The tumours were usually small at presentation with the mean size around 2-4
cm. The largest on record measured 8 cm.
Immune status: Intracranial leiomyomas are commonly associated with immunocompromised
states, however seven of the reported cases were in patients with no known immunodeficiency.
Of the remaining cases 11 were positive for HIV, four were post-transplant recipients
and immune status was unavailable in eight of the patients.
Epstein-Barr virus (EBV) has been implicated in many of these smooth muscle tumours
particularly in association with HIV infection. EBV positivity was noted in 12 cases.
Data on EBV status was unavailable in these 12 cases. Eight cases were both HIV and
EBV positive. Extensive literature is available on the smooth muscle tumours in immunocompromised
patients particularly in association with HIV and EBV infections. However, whether
the association is significant or just a confounding finding given the immunocompromised
state of several of these patients remains unknown. Our patient was positive for both
HIV and HBsAg.
Imaging features: Imaging feature of primary intracranial leiomyoma closely resembles
that of meningioma with hemangiopericytoma, schwannoma, solitary fibrous tumour as
the differentials. The imaging features may resemble lymphoma in the setting of immunosuppression.
Other differentials to be considered include glioblastoma multiforme, intracranial
angioleiomyoma, meningeal sarcoma and metastasis.
Most tumours appeared as hyper dense solid extra axial masses with perifocal oedema
with only one case presenting as a complex cyst. Calcification was reported in four
cases, bone erosion/invasion was reported in two cases and invasion of the superior
sagittal sinus in one case. Invasion into the adjacent pituitary was noted in two
cases. Multifocality was noted in two of the cases, but were still included under
primary intracranial leiomyomas because of low MIB (proliferation index). Limited
literature is available on the MR imaging of these tumours. T1 hypointensity and T2
hyperintensity was seen with homogeneous enhancement post contrast. However, absence
of diffusion is a feature that differentiates it from tumours like lymphoma. Therefore
in an immunocompromised patient with an intracranial extra axial lesion, leiomyoma
should be considered in addition to the usual differentials.[[5]]
Declaration of patient consent
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms.
In the form the patient(s) has/have given his/her/their consent for his/her/their
images and other clinical information to be reported in the journal. The patients
understand that their names and initials will not be published and due efforts will
be made to conceal their identity, but anonymity cannot be guaranteed.